POPULARITY
8 episodes with uncchapel
4 episodes with uncchapel
4 episodes with uncchapel
Love On Panelist 1: Psalms White UNC Student, Class of 2019 UNC Cheerleader Beta Nu Theta Founder & President Panelist 2: Rwenshaun Miller UNC Alum Founder & Executive Director of Eutstress, Inc. Mental Health Advocate Social Entreprenuer Music New Freezer – Rich The Kid feat. Kendrick Lamar Saved – Khalid A Team – Ed Sheeran Warrior – Demi Lovato
Host: Vincent Racaniello Guests: Dirk Dittmer, Cary Moody, Nat Moorman, Nancy Raab-Traub, Lishan Su, and Jennifer Webster-Cyriaque In the first of two shows recorded at the University of North Carolina in Chapel Hill, Vincent meets up with faculty members to talk about how they got into science, their research on DNA viruses, and what they would be doing if they were not scientists. View video of this episode at YouTube Become a patron of TWiV! This episode is brought to you by CuriosityStream, a subscription streaming service that offers over 1,400 documentaries and nonfiction series from the world's best filmmakers. Get unlimited access starting at just $2.99 a month, and for our audience, the first two months are completely free if you sign up at curiositystream.com/microbe and use the promo code MICROBE. This episode is also brought to you by Drobo, a family of safe, expandable, yet simple to use storage arrays. Drobos are designed to protect your important data forever. Visit www.drobo.com to learn more. Listeners can save $100 on a Drobo system at drobostore.com by using the discount code Microbe100. Send your virology questions and comments to twiv@microbe.tv
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly
Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
© 2020-2025 Ivy Podcast Discovery LLC
